miR-34c在制备治疗或预防肝癌的药物或保健品中的应用制造技术

本发明专利技术公开了一种非编码小RNA基因miR-34c在诊断和治疗原发性肝癌中的应用，该miR-34c能够有效抑制HBV相关性肝癌的发生。经研究发现，miR-34c在HBV转基因小鼠肝癌组织和HBV感染的肝癌细胞株显著低表达，且在给予肝癌细胞HepG2.2.15转染miR-34c的表达载体后，miR-34c可以显著抑制HBV?DNA的复制和表达，抑制肝癌细胞的增殖和促进肝癌细胞的凋亡，这表明miR-34c可以有助于早期诊断、预后和治疗HBV相关性肝癌，因此，miR-34c可以用于制备治疗或预防肝癌的药物或保健品，尤其是由HBV感染引起的原发性肝癌。

The use of miR-34c in the preparation of drugs or health-care products for the treatment or prevention of liver cancer

The invention discloses an application of a non coding small RNA gene miR-34c in the diagnosis and treatment of primary liver cancer, and the miR-34c can effectively inhibit the occurrence of HBV related liver cancer. The study found that the expression of miR-34c in hepatocellular carcinoma cell line HBV transgenic mouse liver tissues and HBV infection were significantly lower, and the expression vector given HepG2.2.15 cells transfected with miR-34c, miR-34c can significantly inhibit the expression of DNA and HBV? Replication, proliferation of HCC cells and promote the apoptosis of hepatocellular carcinoma cells, suggesting that miR-34c can contribute to the early diagnosis, prognosis and treatment of HBV related hepatocellular carcinoma, therefore, miR-34c can be used for preparing medicaments or health care products for the treatment or prevention of HCC, especially caused by HBV infection of primary hepatocellular carcinoma.

【技术实现步骤摘要】

【技术保护点】
１．ｍｉＲ－３４ｃ在制备治疗或预防肝癌的药物或保健品中的应用。

【技术特征摘要】

【专利技术属性】
技术研发人员：刘玉刚，王燕，王春梅，范春光，孙汶生，
申请(专利权)人：山东大学，
类型：发明
国别省市：88